HDAC8 and neoplasm: reported that selective inhibition of HDAC8 changes the epigenetic landscape of hepatocellular cancer cells, producing immunostimulatory signatures that work synergistically with anti‐PD‐L1 therapies to enhance T‐cell‐mediated antitumor responses.[52] The ability of HDAC8 to inhibit the transformation of the noninflammatory tumor microenvironment (TME) into a T‐cell inflammatory TME should further accelerate the development of HDAC8‐specific inhibitors for cancer immunotherapy.